Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of JNJ-64007957, a Humanized BCMA * CD3 Bispecific Antibody in Japanese Patients With Relapsed or Refractory Multiple Myeloma

NCT04696809 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.

NCT NCT04696809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04696809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of JNJ-64007957, a Humanized BCMA * CD3 Bispecific Antibody in Japanese Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Janssen Pharmaceutical K.K.
Phase
Phase 1/2
Overall status
Completed
Start date
February 22, 2021
Completion date
April 13, 2026
Enrollment
40 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies